Apixaban Reduces the Incidence of Venous Thrombo Embolism (VTE)

Benefits of the venous thrombo embolism (VTE) drug apixaban when compared to its leading rival Sanofi-aventi's enoxaparin have been published by the staff in clinical research jobs at Pfizer and Bristol-Myers Squibb (BMS). Apixaban has been developed as part of a global collaborative agreement signed by Pfizer and BMS in 2007.

Apixaban, which is administered orally, outperformed enoxaparin in reducing the incidence of venous thrombo embolism (VTE) among patients undergoing elective total hip replacement surgery.

Use of Anticoagulants After Joint Replacement Ops may Lead to More Deaths
A new study from Hospital for Special Surgery in New York has revealed that the use of anticoagulants to prevent blockage in pulmonary artery after joint replacement operations may lead to deaths.

Lead investigator of the study, Dr Michael Rud Lassen of the Hoersholm Hospital in Copenhagen said, "This is encouraging, as the risk of bleeding is a key concern for orthopedic surgeons using oral anticoagulants." In August 2010, clinical data had been published that assessed the effectiveness of apixaban as compared to aspirin, in preventing strokes among atrial fibrillation patients.

Source-Medindia

Anticoagulants is Better for Atrial Fibrillation
People with atrial fibrillation (AF) have irregular heart beats and have a tendency to form blood clots in the upper chambers (atria) of their hearts.

Voice Response System Help to Monitor Patients Taking Anticoagulants
Interactive voice response systems may help improve monitoring of patients taking anticoagulants such as warfarin while reducing the workload of clinical staff.